{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:55:43Z","timestamp":1786121743517,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016298","name":"European Renal Association-European Dialysis and Transplant Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xkme.2026.101419","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:39:20Z","timestamp":1780418360000},"page":"101419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alport Syndrome Family Screening and Management: Experience of a Tertiary Center"],"prefix":"10.1016","volume":"8","author":[{"given":"Ana M.","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Malheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idalina","family":"Beir\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.xkme.2026.101419_bib1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2026.101419_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2026.101419_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","article-title":"A review of clinical characteristics and genetic backgrounds in Alport syndrome","volume":"23","author":"Nozu","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101419_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2215\/CJN.04230321","article-title":"Guidelines for genetic testing and management of Alport syndrome","volume":"17","author":"Savige","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101419_bib6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ndt\/gfae265","article-title":"Diagnosis, management and treatment of the Alport syndrome-2024 guideline on behalf of ERKNet, ERA and ESPN","volume":"40","author":"Torra","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2026.101419_bib7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2026.101419_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101419_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12259","article-title":"The cascade screening in heritable forms of pulmonary arterial hypertension","volume":"13","author":"Varghese","year":"2023","journal-title":"Pulm Circ"},{"issue":"11","key":"10.1016\/j.xkme.2026.101419_bib11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jaip.2022.07.035","article-title":"Prospective study on the efficacy and impact of Cascade Screening and Evaluation of Hereditary Angioedema (CaSE-HAE)","volume":"10","author":"Wong","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","article-title":"Delivery of cascade screening for hereditary conditions: a scoping review of the literature","volume":"37","author":"Roberts","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/genes15050581","article-title":"Genetic screening-emerging issues","volume":"15","author":"Cornel","year":"2024","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.xkme.2026.101419_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jval.2021.11.1353","article-title":"Accounting for intergenerational cascade testing in economic evaluations of clinical genomics: a scoping review","volume":"25","author":"Zischke","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.xkme.2026.101419_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119857","article-title":"Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: insights from molecular simulations and experiments","volume":"240","author":"Yeo","year":"2020","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.xkme.2026.101419_bib16","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.ekir.2024.09.014","article-title":"SGLT2-inhibition in patients with Alport syndrome","volume":"9","author":"Boeckhaus","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101419_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ndt\/gfae180","article-title":"Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport","volume":"40","author":"Gross","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.xkme.2026.101419_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/heartjnl-2011-300368","article-title":"A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy","volume":"98","author":"Ingles","year":"2012","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.xkme.2026.101419_bib19","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101419_bib20","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/ndt\/gfad105","article-title":"Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis","volume":"38","author":"Zeng","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.xkme.2026.101419_bib21","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/ndt\/gfac006","article-title":"Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study","volume":"37","author":"Boeckhaus","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.xkme.2026.101419_bib22","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/ndt\/gfac002","article-title":"Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome","volume":"37","author":"Di","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2026.101419_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/cge.12521","article-title":"Collagen type IV-related nephropathies in Portugal: pathogenic COL4A3 and COL4A4 mutations and clinical characterization of 25 families","volume":"88","author":"Nabais","year":"2015","journal-title":"Clin Genet"},{"issue":"5","key":"10.1016\/j.xkme.2026.101419_bib25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/cge.12522","article-title":"Collagen type IV-related nephropathies in Portugal: pathogenic COL4A5 mutations and clinical characterization of 22 families","volume":"88","author":"Nabais","year":"2015","journal-title":"Clin Genet"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:18:09Z","timestamp":1786083489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2590059526001810"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101419","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alport Syndrome Family Screening and Management: Experience of a Tertiary Center","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101419"}}